Remdesivir

Remdesivir
Clinical data
Pronunciation	/rɛmˈdɛsɪvɪər/ rem-DESS-i-veer
Synonyms	GS-5734
AHFS/Drugs.com	Professional Drug Facts
Routes of; administration	Intravenous
ATC code	None;
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name (2S)-2-{(2R,3S,4R,5R)-[5-(4-Aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxy-tetrahydro-furan-2-ylmethoxy]phenoxy-(S)-phosphorylamino}propionic acid 2-ethyl-butyl ester;
CAS Number	1809249-37-3 ;
PubChem CID	121304016;
DrugBank	DB14761 ;
ChemSpider	58827832;
UNII	3QKI37EEHE;
KEGG	D11472;
ChEBI	CHEBI:145994;
ChEMBL	ChEMBL4065616;
ECHA InfoCard	100.302.974
Chemical and physical data
Formula	C27H35N6O8P
Molar mass	602.58 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCC(COC(=O)[C@@H](NP(=O)(Oc1ccccc1)OC[C@H]1O[C@@]([C@@H]([C@@H]1O)O)(C#N)c1ccc2n1ncnc2N)C)CC;
	InChI InChI=1S/C27H35N6O8P/c1-4-18(5-2)13-38-26(36)17(3)32-42(37,41-19-9-7-6-8-10-19)39-14-21-23(34)24(35)27(15-28,40-21)22-12-11-20-25(29)30-16-31-33(20)22/h6-12,16-18,21,23-24,34-35H,4-5,13-14H2,1-3H3,(H,32,37)(H2,29,30,31)/t17-,21+,23+,24+,27-,42-/m0/s1; Key:RWWYLEGWBNMMLJ-YSOARWBDSA-N;

Remdesivir is a broad-spectrum antiviral medication created by the biopharmaceutical company Gilead Sciences.[1] It was designed to treat Ebola.

As of 2020, remdesivir is being tested as a specific treatment for COVID-19. It is being used for the sickest of patients during the pandemic.[2] It may shorten the time it takes to recover from the infection.[3] Treatment is given by injection into a vein.[4][5]

On May 1, the United States Food and Drug Administration gave doctors permission to use remdesivir on patients with COVID-19. Ordinarily, the FDA would test remdesivir first to see if it worked on patients with COVID-19, but because of the COVID-19 pandemic, they told doctors they could start using the drug before the tests were finished.

In October 2020, the National Institutes of Health told the world the results of its tests: They studied 11,000 people and found that remdesivir did not help keep COVID-19 patients alive. Gilead and some scientists said the results of the tests might not be correct.[6]

References

Scavone C, Brusco S, Bertini M, Sportiello L, Rafaniello C, Zoccoli A, et al. (April 2020). "Current pharmacological treatments for COVID-19: what's next?". British Journal of Pharmacology. 177 (21): 4813–4824. doi:10.1111/bph.15072. PMC 7264618. PMID 32329520.
"Remdesivir EUA Letter of Authorization" (PDF). U.S. Food and Drug Administration (FDA). 1 May 2020. Retrieved 1 May 2020.
Kolata G, Baker P, Weiland N (29 April 2020). "Remdesivir Shows Modest Benefits in Coronavirus Trial". The New York Times. Retrieved 3 May 2020.
"Remdesivir". Drugs.com. Retrieved 30 April 2020.
Mehta N, Mazer-Amirshahi M, Alkindi N (April 2020). "Pharmacotherapy in COVID-19; A narrative review for emergency providers". The American Journal of Emergency Medicine. 38 (7): S0735-6757(20)30263-1. doi:10.1016/j.ajem.2020.04.035. PMC 7158837. PMID 32336586. Archived from the original on 2020-05-02. Retrieved 2020-05-05.
Gina Kolata; Katherine J. Wu (October 15, 2020). "Remdesivir Fails to Prevent Covid-19 Deaths in Huge Trial". New York Times. Retrieved October 21, 2020.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[Scavone_2020-1] Scavone C, Brusco S, Bertini M, Sportiello L, Rafaniello C, Zoccoli A, et al. (April 2020). "Current pharmacological treatments for COVID-19: what's next?". British Journal of Pharmacology. 177 (21): 4813–4824. doi:10.1111/bph.15072. PMC 7264618. PMID 32329520.

[FDA_EUA-2] "Remdesivir EUA Letter of Authorization" (PDF). U.S. Food and Drug Administration (FDA). 1 May 2020. Retrieved 1 May 2020.

[3] Kolata G, Baker P, Weiland N (29 April 2020). "Remdesivir Shows Modest Benefits in Coronavirus Trial". The New York Times. Retrieved 3 May 2020.

[4] "Remdesivir". Drugs.com. Retrieved 30 April 2020.

[Mehta2020-5] Mehta N, Mazer-Amirshahi M, Alkindi N (April 2020). "Pharmacotherapy in COVID-19; A narrative review for emergency providers". The American Journal of Emergency Medicine. 38 (7): S0735-6757(20)30263-1. doi:10.1016/j.ajem.2020.04.035. PMC 7158837. PMID 32336586. Archived from the original on 2020-05-02. Retrieved 2020-05-05.

[NYTFail-6] Gina Kolata; Katherine J. Wu (October 15, 2020). "Remdesivir Fails to Prevent Covid-19 Deaths in Huge Trial". New York Times. Retrieved October 21, 2020.